Syndax announces plans to advance into phase 1b portion of trial evaluating revumenib in relapsed or refractory metastatic mss crc

– idmc recommendation to advance based on favorable safety profile observed in phase 1a portion of trial – waltham, mass. , june 6, 2024 /prnewswire/ -- syndax pharmaceuticals (nasdaq: sndx), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it has advanced into the phase 1b portion of its phase 1/2 proof-of-concept trial of revumenib, the company's highly selective, oral menin inhibitor, as a monotherapy in patients with relapsed or refractory (r/r) metastatic microsatellite stable (mss) colorectal cancer (crc).
MSS Ratings Summary
MSS Quant Ranking